Connection

Campbell McInnes to Molecular Structure

This is a "connection" page, showing publications Campbell McInnes has written about Molecular Structure.
Connection Strength

1.047
  1. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
    View in: PubMed
    Score: 0.175
  2. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
    View in: PubMed
    Score: 0.171
  3. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem. 2020 06 17; 15(12):1058-1066.
    View in: PubMed
    Score: 0.155
  4. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy. Bioorg Med Chem Lett. 2016 08 01; 26(15):3754-60.
    View in: PubMed
    Score: 0.118
  5. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42.
    View in: PubMed
    Score: 0.107
  6. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov; 2(11):608-17.
    View in: PubMed
    Score: 0.060
  7. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs. 2006 Apr; 9(4):273-8.
    View in: PubMed
    Score: 0.058
  8. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 2004 Apr; 11(4):525-34.
    View in: PubMed
    Score: 0.051
  9. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
    View in: PubMed
    Score: 0.042
  10. Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor a and ? subtypes: a molecular modeling study. PLoS One. 2013; 8(9):e74615.
    View in: PubMed
    Score: 0.024
  11. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
    View in: PubMed
    Score: 0.018
  12. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chembiochem. 2006 Dec; 7(12):1909-15.
    View in: PubMed
    Score: 0.015
  13. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chem Biol. 2006 Feb; 13(2):201-11.
    View in: PubMed
    Score: 0.014
  14. Protein structures in virtual screening: a case study with CDK2. J Med Chem. 2006 Jan 12; 49(1):92-104.
    View in: PubMed
    Score: 0.014
  15. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem. 2004 Mar 25; 47(7):1662-75.
    View in: PubMed
    Score: 0.013
  16. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure. 2003 Apr; 11(4):399-410.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.